These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 24340644)

  • 41. Particulate and vesicular drug carriers in the management of tuberculosis.
    Rastogi R; Sultana Y; Ali A; Aqil M
    Curr Drug Deliv; 2006 Jan; 3(1):121-8. PubMed ID: 16472101
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nanocarriers for oral drug delivery.
    Zhang L; Wang S; Zhang M; Sun J
    J Drug Target; 2013 Jul; 21(6):515-27. PubMed ID: 23621127
    [TBL] [Abstract][Full Text] [Related]  

  • 43. pH-sensitive polymeric nanoparticles to improve oral bioavailability of peptide/protein drugs and poorly water-soluble drugs.
    Wang XQ; Zhang Q
    Eur J Pharm Biopharm; 2012 Oct; 82(2):219-29. PubMed ID: 22885229
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nanoemulsion for the Effective Treatment and Management of Anti-tubercular Drug Therapy.
    Beg S; Saini S; Imam SS; Rahman M; Swain S; Hasnain MS
    Recent Pat Antiinfect Drug Discov; 2017; 12(2):85-94. PubMed ID: 28480833
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Experimental studies on the effective regimens of antituberculous drugs in the treatment of tuberculosis. II. Long-term chemotherapy in mice by daily and intermittent administration with changing drug combination (author's transl)].
    Kondo E; Kanai K
    Kekkaku; 1977 Aug; 52(8):373-6. PubMed ID: 916488
    [No Abstract]   [Full Text] [Related]  

  • 46. Improved transport and absorption through gastrointestinal tract by PEGylated solid lipid nanoparticles.
    Yuan H; Chen CY; Chai GH; Du YZ; Hu FQ
    Mol Pharm; 2013 May; 10(5):1865-73. PubMed ID: 23495754
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Inhaled Solid Lipid Microparticles to target alveolar macrophages for tuberculosis.
    Maretti E; Rossi T; Bondi M; Croce MA; Hanuskova M; Leo E; Sacchetti F; Iannuccelli V
    Int J Pharm; 2014 Feb; 462(1-2):74-82. PubMed ID: 24374224
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Design and evaluation of polymer coated carvedilol loaded solid lipid nanoparticles to improve the oral bioavailability: a novel strategy to avoid intraduodenal administration.
    Venishetty VK; Chede R; Komuravelli R; Adepu L; Sistla R; Diwan PV
    Colloids Surf B Biointerfaces; 2012 Jun; 95():1-9. PubMed ID: 22463845
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Alginate-based oral drug delivery system for tuberculosis: pharmacokinetics and therapeutic effects.
    Qurrat-ul-Ain ; Sharma S; Khuller GK; Garg SK
    J Antimicrob Chemother; 2003 Apr; 51(4):931-8. PubMed ID: 12654730
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Recent developments in nanoparticles for the treatment of diabetes.
    Sharma DK; Pattnaik G; Behera A
    J Drug Target; 2023 Dec; 31(9):908-919. PubMed ID: 37725445
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Modeling nanoparticle delivery of TB drugs to granulomas.
    Grobler A; Perez Sierra Z; Viljoen HJ
    J Theor Biol; 2016 Jan; 388():85-95. PubMed ID: 26493361
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Therapeutic problems in the management of elderly patients with tuberculosis.
    Woo J; Chan HS
    Adverse Drug React Toxicol Rev; 1992; 11(1):13-8. PubMed ID: 1606279
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Poly(lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel.
    Feng SS; Mei L; Anitha P; Gan CW; Zhou W
    Biomaterials; 2009 Jul; 30(19):3297-306. PubMed ID: 19299012
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A novel approach to oral iron delivery using ferrous sulphate loaded solid lipid nanoparticles.
    Zariwala MG; Elsaid N; Jackson TL; Corral López F; Farnaud S; Somavarapu S; Renshaw D
    Int J Pharm; 2013 Nov; 456(2):400-7. PubMed ID: 24012860
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lung specific stealth liposomes as antitubercular drug carriers in guinea pigs.
    Pandey R; Sharma S; Khuller GK
    Indian J Exp Biol; 2004 Jun; 42(6):562-6. PubMed ID: 15260105
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Recent bioequivalence studies on fixed-dose combination anti-tuberculosis drug formulations available on the global market.
    Pillai G; Fourie PB; Padayatchi N; Onyebujoh PC; McIlleron H; Smith PJ; Gabriels G
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S309-16; discussion S317-21. PubMed ID: 10593710
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [The relation between bacilli negative conversion rate and the number of combined sensitive antituberculous drugs in intermittent administration of rifampicin for severe pulmonary tuberculosis].
    Tamura M; Yamazaki A; Tamura T; Takano S; Yamazaki M
    Kekkaku; 1973 Jul; 48(7):297-302. PubMed ID: 4200058
    [No Abstract]   [Full Text] [Related]  

  • 58. Lipid nanoparticles as drug/gene delivery systems to the retina.
    del Pozo-Rodríguez A; Delgado D; Gascón AR; Solinís MÁ
    J Ocul Pharmacol Ther; 2013 Mar; 29(2):173-88. PubMed ID: 23286300
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Desensitization therapy for antituberculous drugs].
    Kobashi Y; Okimoto N; Matsushima T; Abe T; Nishimura K; Shishido S; Kawahara S; Shigeto E; Takeyama H; Kuraoka T
    Kekkaku; 2000 Sep; 75(9):521-6. PubMed ID: 11068368
    [TBL] [Abstract][Full Text] [Related]  

  • 60. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.